http://orcid.org/0000-0003-4123-4148
References
- Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58–69. doi:10.1016/j.jpainsymman.2005.06.007.
- Parshall MB, Schwartzstein RM, Adams L, et al. An Official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452. doi:10.1164/rccm.201111-2042ST.
- Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148(2):141–146. doi:10.7326/0003-4819-148-2-200801150-00009.
- Worsley MH, Macleod AD, Brodie MJ, et al. Inhaled fentanyl as a method of analgesia. Anaesthesia. 1990;45(6):449–451. doi:10.1111/j.1365-2044.1990.tb14331.x.
- Mather LE, Woodhouse A, Ward ME, et al. Pulmonary administration of aerosolized fentanyl: pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol. 1998;46(1):37–43. doi:10.1046/j.1365-2125.1998.00035.x.
- Miner JR, Kletti C, Herold M, Hubbard D, et al. Randomized clinical trial of nebulized fentanyl citrate versus i.v. fentanyl citrate in children presenting to the emergency department with acute pain. Acad Emerg Med. 2007;14(10):895–898. doi:10.1197/j.aem.2007.06.036.
- Simon ST, Köskeroglu P, Gaertner J, et al. Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage. 2013;46(6):874–886. doi:10.1016/j.jpainsymman.2013.02.019.
- Wahler RG, Jr. Smith DB, Mulcahy KB. Nebulized fentanyl for dyspnea in a hospice patient with true allergy to morphine and hydromorphone. J Pain Palliat Care Pharmacother. 2017;31(1):38–42.
- Graff GR, Stark JM, Grueber R. Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration. 2004;71(6):646–649. doi:10.1159/000081769.
- Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012;43(4):706–719. doi:10.1016/j.jpainsymman.2011.05.007.
- Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients’ perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage. 2002;23(2):157–160. doi:10.1016/S0885-3924(01)00391-8.
- Simon ST, Niemand AM, Benalia H, et al. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 2012;15(12):1374–1381. doi:10.1089/jpm.2012.0249.
- Boyden JY, Connor SR, Otolorin L, et al. Nebulized medications for the treatment of dyspnea: a literature review. J Aerosol Pulm Drug Deliv. 2015;28(1):1–19. doi:10.1089/jamp.2014.1136.
- Afolabi TM, Nahata MC, Pai V. Nebulized opioids for the palliation of dyspnea in terminally ill patients. Am J Health Syst Pharm. 2017;74(14):1053–1061. doi:10.2146/ajhp150893.
- Barke KE, Hough LB. Opiates, mast cells, and histamine release. Life Sci. 1993;53(18):1391–1399. doi:10.1016/0024-3205(93)90581-M.